Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Amfecloral** is a discontinued orally administered small-molecule anorectic that was marketed in the United States as **Acutran** for obesity. It is an amphetamine-class imine prodrug formed from dextroamphetamine and chloral hydrate; following metabolism, it releases amphetamine-related stimulant activity and chloral-hydrate-related sedative-hypnotic activity. The sedative component was thought to offset the stimulant effects, and the product was characterized as having limited stimulant activity. Acutran was withdrawn from the market in 1973.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amfecloral.